ERBB2 and breast cancer: Moreover, as we could observe, a specific advantage of anti-HER2 vaccines for BC treatment is that they can yield clinical efficacy especially when HER2 protein presents an intermediate level of expression, which could extend the ground of action for an HER2-directed immunotherapeutic strategy.